Peer-reviewedLicence not statedFuture Oncology
Gedatolisib for the treatment of hormone receptor-positive/HER2-negative advanced breast cancer: a European perspective
- 1Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy
- 2Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
Related
- Targeting the PI3K/AKT/mTOR pathway in endocrine-resistant, hormone receptor-positive, HER2-negative, advanced breast cancer
- CDK4/6 Inhibitors in the Treatment of Advanced ER/PR-Positive, HER2-Negative Breast Cancer: An Updated Single-Center Analysis of Real-World Data
- Neoadjuvant Chemotherapy Increases Genomic Radioresistance in Hormone Receptor–positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Implications for Radiation Sensitivity Index/Genomic-Adjusted Radiation Dose–Guided Radiation Therapy Personalization
- Hormone receptor–positive HER2-negative oligometastatic breast cancer: prognostic stratification and pattern of progression
- Integrated CDK4/6 inhibitor resistance and primary-metastatic discordance in hormone receptor-positive/HER2-negative metastatic breast cancer: a translational framework focused on invasive ductal carcinoma with gastric metastasis.
BibTeX
@article{matera2026gedatolisib,
title = {{Gedatolisib for the treatment of hormone receptor-positive/HER2-negative advanced breast cancer: a European perspective}},
author = {Letizia Matera and Julian David Etessami and Carmine Valenza and Giuseppe Curigliano},
journal = {Future Oncology},
year = {2026},
month = oct,
doi = {10.1080/14796694.2026.2742759},
url = {https://doi.org/10.1080/14796694.2026.2742759},
}
RIS
TY - JOUR
TI - Gedatolisib for the treatment of hormone receptor-positive/HER2-negative advanced breast cancer: a European perspective
AU - Letizia Matera
AU - Julian David Etessami
AU - Carmine Valenza
AU - Giuseppe Curigliano
PY - 2026
DA - 2026/10/05
JO - Future Oncology
DO - 10.1080/14796694.2026.2742759
UR - https://doi.org/10.1080/14796694.2026.2742759
SN - 1479-6694
SN - 1744-8301
ER -